既往缺血性卒中患者极低LDL-C水平的疗效与安全性
基于FOURIER随机安慰剂对照试验及其开放标签延伸期,分析5291例既往缺血性卒中患者,按达标LDL-C分层。结果显示LDL-C越低(至<40 mg/dL),主要终点、全因卒中和缺血性卒中发生率单调降低,出血性卒中罕见且与LDL-C无关。提示既往缺血性卒中患者强化降脂可能获益。
要点
- 既往缺血性卒中患者LDL-C降至<40 mg/dL时主要心血管事件风险更低
- LDL-C水平与全因卒中和缺血性卒中发生率呈单调负相关
- 出血性卒中罕见且与达标LDL-C水平无显著关联
核心结论
- 在既往缺血性卒中患者中,LDL-C降至<40 mg/dL时主要不良心血管事件(包括复发性卒中)风险更低,且未明显增加出血性卒中风险。
研究设计与样本
- 分析FOURIER随机安慰剂对照试验中既往缺血性卒中(>4周)患者5291例,中位随访2.2年,并延伸至FOURIER-OLE开放标签期(额外中位随访5年)。
主要发现
- 达标LDL-C <20、20至<40、40至<55、55至<70、≥70 mg/dL的患者分别为666例(12.6%)、1410例(26.6%)、586例(11.1%)、508例(9.6%)和2121例(40.1%)。
- 主要终点、全因卒中和缺血性卒中发生率随达标LDL-C降低呈单调下降(Ptrend<0.001、0.002、0.002)。
- 与LDL-C≥70 mg/dL相比,达标<40 mg/dL者主要终点、全因卒中和缺血性卒中的发生率比分别为0.69(95%CI 0.57-0.84)、0.73(95%CI 0.53-0.99)和0.75(95%CI 0.54-1.05)。
- 出血性卒中罕见,且与达标LDL-C无关(Ptrend=0.85)。
临床怎么用
- 对既往缺血性卒中患者,可考虑更强化地降低LDL-C至<40 mg/dL以降低主要心血管事件和复发性卒中风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear. METHODS: We analyzed patients with previous ischemic stroke enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), a randomized placebo-controlled trial studying evolocumab in patients with stable atherosclerotic cardiovascular disease (median follow-up, 2.2 years), and through the open-label extension (FOURIER-OLE) period (additional median follow-up, 5 years), to examine the relationship between achieved LDL-C and the long-term incidence of the primary end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization) and stroke-related end points. RESULTS: The analysis included 5291 patients with previous ischemic stroke (>4 weeks). Of these, 666 (12.6%), 1410 (26.6%), 586 (11.1%), 508 (9.6%), and 2121 (40.1%) patients achieved LDL-C values of <20, 20 to <40, 40 to <55, 55 to <70, and ≥70 mg/dL, respectively. The incidence of the primary end point, all stroke, and ischemic stroke each decreased in a monotonic fashion with lower achieved LDL-C levels on a continuous scale (Ptrend<0.001, 0.002, and 0.002, respectively). Compared with patients with LDL-C ≥70 mg/dL, those who achieved levels <40 mg/dL had incidence rate ratios of 0.69 (95% CI, 0.57-0.84), 0.73 (95% CI, 0.53-0.99), and 0.75 (95% CI, 0.54-1.05) for the outcomes of the primary end point, all stroke, and ischemic stroke, respectively. Hemorrhagic strokes were infrequent and unrelated to achieved LDL-C (Ptrend=0.85). CONCLUSIONS: In patients with previous ischemic stroke, it appeared that the lower the LDL-C, down to levels <40 mg/dL, the lower the risk of major adverse cardiovascular events, including recurrent stroke, without a clear increase in risk of hemorrhagic stroke. These findings support the concept that more intensive LDL-C lowering in patients with previous ischemic stroke may be warranted. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01764633/NCT01764633.
引用
- Monguillon V, Kelly PJ, O'Donoghue ML, et al. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation. 2025. PMID: 41178569. doi:10.1161/CIRCULATIONAHA.125.077549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。